Abivax stock surges 9% on trial results for ulcerative colitis therapy
Abivax SA stock lifted nearly 9% in Tuesday morning trade after the company released positive results for its ulcerative colitis therapy, ABX464-101, from a phase 2a clinical trial. The trial enrolled 32 patients with moderate-to-severe ulcerative colitis, 29 of which have completed the study so far. After eight weeks of treatment, 35% of individuals on the therapy were in clinical remission, and 70% achieved a clinical response, relative to 11% and 20% of individuals on the placebo, respectively. About half of individuals on the therapy exhibited healing of the internal, mucosal membrane as measured by an endoscopy, compared with about 11% of those on the placebo. Both clinical and endoscopic endpoints in the trial were statistically significant, according to Abivax. Ulcerative colitis is an inflammatory bowel disease marked by inflammation and ulcers in the digestive tract; though a number of medications exist, not all patients respond to them, the company noted. Patients who participated in the phase 2a trial had previously failed when taking other treatments, including immunomodulators, anti-TNFα, vedolizumab and/or corticosteroids. Abivax shares have lifted 1.7% over the last three months, compared with a 5.2% rise in the S&P 500 and a 4.4% rise in the Dow Jones Industrial Average .
Source : MTV
